Torsin-1A helps CLCC1 proteins fuse the two nuclear membranes so pores can form
ETH Zurich-led teams report in Molecular Cell that fusing a cell's two nuclear membranes for a new pore takes both Torsin-1A and CLCC1 proteins. They tie the mechanism to DYT1 dystonia, which affects about six in 100,000 people, and propose raising CLCC1 as a possible therapy.
The Scientist · Science desk
Five actors: Torsin-1A binds CLCC1 and accompanies it to the pore site; simulations led to a hypothesized temporary CLCC1 lipid channel; a Torsin1A mutation leaves CLCC1 short of support in primary dystonia; about a third of carriers show symptoms; raising CLCC1 corrected fly defects.
- capability Torsin-1A Binds CLCC1, helps several units join, then accompanies the complex to the pore assembly site, claim 5
- capability CLCC1 complex Simulations led researchers to hypothesize a temporary channel that lets lipids cross the bilayers, claim 9
- exposure People with primary dystonia A Torsin1A mutation stops the molecule working correctly, leaving CLCC1 with insufficient support, claim 6
- exposure Torsin-1A mutation carriers About a third develop symptoms; why is still unclear, claim 17
- precedent Fruit flies Raising CLCC1 levels corrected defects, for example in germline cell development, claim 12
| Who | How | Kind | Claim |
|---|---|---|---|
| Torsin-1A | Binds CLCC1, helps several units join, then accompanies the complex to the pore assembly site | capability | 5 |
| CLCC1 complex | Simulations led researchers to hypothesize a temporary channel that lets lipids cross the bilayers | capability | 9 |
| People with primary dystonia | A Torsin1A mutation stops the molecule working correctly, leaving CLCC1 with insufficient support | exposure | 6 |
| Torsin-1A mutation carriers | About a third develop symptoms; why is still unclear | exposure | 17 |
| Fruit flies | Raising CLCC1 levels corrected defects, for example in germline cell development | precedent | 12 |
What happened
- Torsin-1A binds CLCC1, helps several of the building blocks join, then travels with the complex to the site where the pore is assembled.
- Computer simulations led the researchers to hypothesize that CLCC1 forms a temporary channel in the envelope, letting lipids cross the bilayers and destabilize the local membrane until the two membranes fuse.
- In people with primary dystonia, a mutation in the Torsin1A gene stops the molecule working properly and leaves the CLCC1 complex without enough support.
- Only about a third of Torsin1A mutation carriers develop symptoms, and the reason is still unclear.
Why it matters
- constraint The fly example the account gives is germline cell development, a cellular readout, so it does not show that a movement disorder was corrected.
- contradiction The account says the teams solved how cells open and seal both membranes, yet it describes the fusion step itself as a hypothesis built on computer simulations.
- decision The strategies on the table are boosting CLCC1 production or blocking its breakdown, and the account says clinical studies and drug screens must come before anyone knows whether either works in people.
Part of the picture was already in place. A defect in Torsin-1A was known to halt nuclear pore assembly, with fatal consequences for the cell [4]. The new claim concerns its partner. According to the ETH Zurich account carried by phys.org, the researchers have shown for the first time that fusing the envelope's two membranes requires both the enzyme Torsin-1A and a complex of several CLCC1 units in humans, or the fungal counterparts Brl1 and Brr6 [3]. Groups at ETH Zurich, the University of Fribourg, the Paul Scherrer Institute, EMBL and RWTH Aachen University took part [8].
The exact fusion mechanism caught the teams by surprise [10]. Daria Maslennikova, first author of one of the studies, who completed her doctorate in Kutay's group, said: "We had not expected such a mechanism." [11]
On who gets symptoms, the account offers a hypothesis. The researchers speculate that person-specific differences in CLCC1 protein levels may contribute [18]. In our view, a difference in CLCC1 between carriers would stay a correlation until someone compared carriers with and without symptoms, and then changed the levels and watched what followed.
ETH professor Ulrike Kutay said: "This finding helps us envision a possible therapy." [13] The strategy under discussion has already shown success in human cell cultures and in fruit flies, according to the account [15]. The thing this does not tell you is how large the effect was. Sample sizes and effect sizes for the fly and cell-culture work are not in the account, and neither is any direct test of the lipid channel beyond the simulations.
What to watch
- Drug screens and clinical studies of CLCC1 boosting or stabilisation, the step the account says must come before any claim about people.
- A direct experimental test of the proposed lipid channel formed by CLCC1, Brl1 and Brr6, beyond the simulations.
- A comparison of CLCC1 levels in Torsin1A mutation carriers with and without symptoms.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence55
- Adoption
- Insufficient
- Hype gap+20
- Incentives
- Insufficient
- Confidence45
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Before a nuclear pore complex can be assembled, the cell must punch an opening through both nuclear membranes and then seal the edges; how cells do this was a long-standing puzzle.
- [2]
Research teams at the Institute of Biochemistry, led by ETH professors Ulrike Kutay, Karsten Weis and Madhav Jagannathan, with colleagues from the University of Fribourg and other partners, say they have solved the puzzle; the studies were published in Molecular Cell.
- [3]
The researchers say they have shown for the first time that two tools are required for the envelope's two membranes to fuse: the enzyme Torsin-1A and a complex of several CLCC1 units (in humans) or their fungal counterparts, Brl1 and Brr6.
- [4]
It was already known that a defect in Torsin-1A halts nuclear pore assembly, with fatal consequences for the cell.
- [5]
Torsin-1A binds to CLCC1 and helps several of these building blocks join together, then accompanies the CLCC1 complex to the site of pore assembly to enable membrane fusion.
- [6]
In humans with primary dystonia, a mutation in the Torsin1A gene prevents the Torsin1A molecule from functioning correctly, leaving the CLCC1 complex with insufficient support.
- [7]
Primary dystonia (DYT1 dystonia) is a rare, currently incurable neurological movement disorder that affects about six in 100,000 people worldwide.
- [8]
The work resulted from collaboration among research groups at ETH Zurich, the University of Fribourg, the Paul Scherrer Institute (PSI), the European Molecular Biology Laboratory (EMBL) and RWTH Aachen University.
- [9]
Using computer simulations, the researchers hypothesized that CLCC1 proteins (or Brl1 and Brr6 in fungi) forge a temporary channel inside the nuclear envelope, allowing lipids to flow across the bilayers, destabilizing the local membrane and forcing the two nuclear membranes to fuse.
- [10]
The exact mechanism of the fusion caught the research teams by surprise.
- [11]
Daria Maslennikova, first author of one of the studies, who completed her doctorate in Kutay's group, said: "We had not expected such a mechanism."
- [12]
In fruit fly (Drosophila) experiments, the researchers showed that artificially increasing CLCC1 levels can correct defects that occur, for example, during germline cell development.
- [13]
ETH professor Ulrike Kutay said: "This finding helps us envision a possible therapy."
- [14]
One potential treatment strategy could be to boost CLCC1 production or prevent the protein from breaking down.
- [15]
The strategy of boosting CLCC1 has already shown success in human cell cultures and in fruit flies.
- [16]
Whether these findings can be successfully translated to humans must first be evaluated in further clinical studies and drug screens.
- [17]
An alteration in the Torsin-1A gene causes symptoms in only about a third of mutation carriers, and why is still unclear.
- [18]
The researchers speculate that person-specific differences in CLCC1 protein levels may contribute to why only about a third of mutation carriers have symptoms.
Sources
1 independent publisher whose own reporting we read for this story.
- phys.orgHow cells make their command center accessible
1 article · October 13, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Entities
- Ulrike KutayFollow
- Molecular CellFollow
- ETH ZürichFollow
- CLCC1Follow
- Torsin-1AFollow